Targets › CDK7
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Aug 2028.
Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. As a cyclin-dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and the CDK-activating kinase assembly factor MAT1. (UniProt, P50613)
Open in Phaseline: the race on CDK7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Zotiraciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor | CDK1, CDK2, CDK7, CDK9, FLT3 | Phase 1 | Brain Tumor | Aug 2028 |
| Qurient | Q901 Highly selective CDK7 inhibitor | CDK7 | Phase 1 | Advanced Cancer | – |
Brain Tumor (1) Advanced Cancer (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.